Real-world oral glucocorticoid use in SLE: a nation-wide population-based study using the French medico-administrative (SNDS) claim database.

Background: Oral glucocorticoids (OCS) remain one of the most important treatments for SLE but are associated with damage. Evidence regarding the real-world use of OCS in nationwide SLE populations is currently lacking. The aim of this study was to analyse OCS use and SLE treatments in French patients with SLE at the national level.

Economic burden of systemic lupus erythematosus and lupus nephritis in France: a nationwide population-based study using the French medico-administrative (SNDS) claims database.

Objectives: Data on the economic consequences of systemic lupus erythematosus (SLE) and lupus nephritis (LN) are scarce in Europe. We aimed to estimate the total direct costs attributable to SLE and LN in France, at the nationwide level.

Methods: Patients with SLE and LN were identified in the French nationwide health insurance database (SNDS).